Transcript Dia 1

PARTNER trial
Objective:
To compare the efficacy and safety of TAVI
with standard therapy in high risk patients
deemed not suitable for surgery.
Study:
Multicenter, randomized trial.
Population: Patients with severe aortic stenosis
(AVA < 0.8 cm2), deemed inoperable.
No concomitant CAD, no LVEF < 20%, no renal
failure, no severe MR or AR. No bicuspid valve,
no recent stroke.
Endpoint: All cause mortality, Death or repeat
hospitalization.
PARTNER trial
TAVI
Edwards SAPIEN valve
N=179
Patients enrolled
N=358
Standard therapy
Including balloon valvuloplasty
N=179
PARTNER trial
Event rate at 1 year f-up (%)
P<0.001
P<0.001
P<0.001
TAVI
P=0.04
Standard therapy
71,6
80
60
40
P<0.001
50,7
58,0
42,5
30,7
25,2
20
32,4
7,3
10,6
4,5
0
Death
Death/repeat
hosp.
NYHA III/IV
vasc compl
Stroke/TIA
PARTNER trial
Conclusion: In patients with severe aortic stenosis who
were not suitable for surgery TAVI reduced
the rate of death, death or repeat hospitalization
and cardiac symptoms, despite a higher
incidence of stroke and vascular events.
Leon et al. N Engl J Med 2010;363:1597-1607